Veracyte Announces SITC 2023 Presentations Offering New Insight into Immuno-oncology Drug Development
27 10월 2023 - 9:30PM
Business Wire
Two abstracts show the potential for using
Veracyte’s tools to characterize the tumor microenvironment
Veracyte, Inc. (Nasdaq: VCYT) today announced that two poster
presentations taking place at SITC 2023, the annual meeting of the
Society for Immunotherapy of Cancer, in San Diego from November 3-5
will demonstrate the potential for using the company’s novel tools
to help advance the development of immuno-oncology drugs. These
tools allow for better characterization of the tumor
microenvironment (TME), which can enable new insights into drug
response and mechanisms of resistance.
“While immunotherapy drugs such as immune checkpoint inhibitors
have been shown to induce remarkable, long-term responses in many
cancer types, they remain ineffective for a majority of patients.
There is a pressing need to understand drug response so scientists
can develop treatments that will be effective for many more
patients and types of cancer,” said Corinne Danan, Veracyte’s
general manager of Biopharma and IVD Services. “These conference
presentations will show that Veracyte’s Brightplex and Immunoscore
IC tools can offer scientists a clearer view of the tumor
microenvironment, as well as data that could inform immuno-oncology
drug development.”
The following posters will be presented at the SITC 2023 meeting
on Saturday, November 4, 2023:
Title: Deciphering the relationship between lymphocytes
and macrophages within the tumor micro-environment using a workflow
combining RNA transcripts detection and multiplex IHC on
Brightplex® Presenter: Jacques Fieschi, Ph.D., VP, research
and development, Veracyte Abstract: #70 Location:
Exhibit Halls A and B1
Title: Regulatory T-cell tumor infiltration improves
advanced NSCLC patients’ outcome under ≥ 2nd line
anti-PD1/L1monotherapy in The PIONeeR Project Presenter:
Florence Monville, Ph.D., Scientific Head of Collaborative Research
Projects at Veracyte Abstract: #782-C Location:
Exhibit Hall B
In addition, Veracyte will host the following corporate
symposium on Friday, November 3, 2023, from 5:10 p.m. to 6:40 p.m.
PT:
Title: A Promising Biomarker of Tumor Immunogenicity:
Unveiling the Potential of Immunoscore IC® (CD8/PDL1)
Presenters: Jérôme Galon, Ph.D. (scientific executive
director, Veracyte); Jacques Fieschi, Ph.D. (VP, research and
development, Veracyte) Location: Presentation Stage
(Exhibition Floor)
About Veracyte Veracyte (Nasdaq: VCYT) is a global
diagnostics company whose vision is to transform cancer care for
patients all over the world. We empower clinicians with the
high-value insights they need to guide and assure patients at
pivotal moments in the race to diagnose and treat cancer. Our
high-performing tests enable clinicians to make more confident
diagnostic, prognostic, and treatment decisions for some of the
most challenging diseases such as thyroid, prostate, breast,
bladder and lung cancers, as well as interstitial lung diseases. We
help patients avoid unnecessary procedures and speed time to
diagnosis and appropriate treatment. In addition to making our
tests available in the U.S. through our central laboratories, we
also aim to deliver our tests to patients worldwide through a
distributed model to laboratories that can perform them locally.
For more information, please visit www.veracyte.com and follow the
company on Twitter (@veracyte).
Cautionary Note Regarding Forward-Looking Statements This
press release contains forward-looking statements, including, but
not limited to our statements related to our plans, objectives,
expectations (financial and otherwise) or intentions with respect
to our clinical tests in and outside of the United States.
Forward-looking statements can be identified by words such as:
“appears,” "anticipate," "intend," "plan," "expect," "believe,"
"should," "may," "will," “positioned,” “designed” and similar
references to future periods. Examples of forward-looking
statements include, among others, that Veracyte’s Brightplex and
Immunoscore IC tools can offer scientists a clearer view of the
tumor microenvironment, as well as data that could inform
immuno-oncology drug development. Additional factors that may
impact these forward-looking statements can be found under the
caption “Risk Factors” in our Annual Report on Form 10-K filed on
March 1, 2023, and our Quarterly Report on Form 10-Q filed for the
three months ended June 30, 2023. Copies of these documents, when
available, may be found in the Investors section of our website at
https://investor.veracyte.com. These forward-looking statements
speak only as of the date hereof and, except as required by law, we
specifically disclaim any obligation to update these
forward-looking statements or reasons why actual results might
differ, whether as a result of new information, future events or
otherwise.
Veracyte, the Veracyte logo, Brightplex, and Immunoscore IC are
registered trademarks of Veracyte, Inc. and its subsidiaries in the
U.S. and selected countries. Brightplex and Immunoscore IC are
available for clinical research. Those tests have not been cleared
nor approved by the FDA and are not for use in diagnostic
procedures.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231027584682/en/
Investors: investors@veracyte.com 619-393-1545
Media: Tracy Morris VP of Global Corporate Communications
tracy.morris@veracyte.com 650-380-4413
Veracyte (NASDAQ:VCYT)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Veracyte (NASDAQ:VCYT)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024